Clinical trial · Interventional
The Safety and Effect Study of Acupuncture for Anorexia in Patients With Gastrointestinal Tract and Lung Cancers
The Traditional Chinese Medicine Department of Xin Qiao Hospital
NCT02619266CI-TRIAL-00020060unknownPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This trail will be carried out to evaluated the effect and safety of acupuncture for the anorexia in patients with gastrointestinal tract and lung cancers.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anorexia | — | UNRESOLVED | — |
| Cancer Cachexia | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Acupuncture | Other | — | UNRESOLVED |
| Megestrol Acetate | Drug | Megestrol | ALIAS |
| Placebo(Megestrol Acetate) | Drug | — | UNRESOLVED |
| Sham Acupuncture | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Acupuncture+Placebo
- description
- Acupuncture once daily for 7 days and Placebo tablet by mouth, twice a day for 7 days.
- interventionNames
- Other: Acupuncture
- Drug: Placebo(Megestrol Acetate)
- type
- ACTIVE_COMPARATOR
- label
- Megestrol Acetate+Sham acupuncture
- description
- Megestrol Acetate tablet 160mg by mouth, twice a day for 7 days and Sham Acupuncture once a day for 7 days .
- interventionNames
- Other: Sham Acupuncture
- Drug: Megestrol Acetate
- type
- PLACEBO_COMPARATOR
- label
- Placebo+Sham acupuncture
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Diagnosed gastrointestinal tand lung cancers; 2. Age ≥18 years; 3. Appetite score≤ 6 (0= worst appetite), and the symptom lasted 2 weeks at lest at screening; 4. Had a history of weight loss ≥5% within 6 moths; 5. Maintained oral intake; 6. Signed the informed consent. Exclusion Criteria: 1. Patients with dementia, delirium, intestinal obstruction, pregnancy or lactation; 2. Had uncontrolled symptoms that could impact appetite or caloric intake such as nausea, pain, or depression(The score of the symptoms≤ 3, 0= worst) ; 3. Patients with untreated vitamin B12 deficiency or endocrine abnormalities(thyroid dysfunction and hypoadrenalism); 4. Patients on melatonin supplements or medications with potential appetite-stimulating activity(Chinese herb,thalidomide) 5. Less than one week before the screening or there will be a surgery ,radiotherapy and chemotherapy the acupuncture; 6. Lifetime expected less than 3 months.
References
Publications (3)
- BACKGROUNDDel Fabbro E, Dev R, Hui D, Palmer L, Bruera E. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol. 2013 Apr 1;31(10):1271-6. doi: 10.1200/JCO.2012.43.6766. Epub 2013 Feb 25. PMID 23439759
- BACKGROUNDBruera E, Strasser F, Palmer JL, Willey J, Calder K, Amyotte G, Baracos V. Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: a double-blind, placebo-controlled study. J Clin Oncol. 2003 Jan 1;21(1):129-34. doi: 10.1200/JCO.2003.01.101. PMID 12506181
- BACKGROUNDBruera E, Macmillan K, Kuehn N, Hanson J, MacDonald RN. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer. 1990 Sep 15;66(6):1279-82. doi: 10.1002/1097-0142(19900915)66:63.0.co;2-r. PMID 2205358